http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2024, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 28 Aug 2024 02:01:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/PureTech+Health+plc%C2%A0%E2%80%93+Half-Year+Report/23653183.html <p class="bwalignc"> <i>Strong progress across PureTech’s portfolio, with significant near-term catalysts</i> </p><p class="bwalignc"> <i>Robust shareholder returns enabled by Founded Entity1 monetization; $100 million Tender Offer and </i><i>$50 million buyback completed</i> </p><p class="bwalignc"> <i>Strong balance sheet with expected operational runway for at least three years</i> </p><p class="bwalignc"> <i>Company to host a webcast and conference call today at 9:00am EDT / 2:00pm BST</i> </p> <p> BOSTON--(BUSINESS WIRE)-- PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announces its half-yearly results for the six months ended June 30, 2024. The following information will http://www.streetinsider.com/Press+Releases/PureTech+Health+plc%C2%A0%E2%80%93+Half-Year+Report/23653183.html Wed, 28 Aug 2024 02:01:00 -0400 A.01362791 A.06822034 A.09542560 A.21794726 A.26940647 A.27675538 A.31066700 A.31197700 A.37672378 A.40871480 A.50114120 A.60004854 A.60012007 A.60012014 AKLI BMY O.00000283 O.00384710 O.00417799 O.00638181 O.00831659 O.00831932 O.10864893 O.20026344 O.22422661 O.22973220 O.28834655 O.41197774 O.41343427 O.48279457 PRTC PRTC VOR http://www.streetinsider.com/Press+Releases/PureTech+Health+plc%C2%A0%E2%80%93+Half-Year+Report/23653183.html <p class="bwalignc"> <i>Strong progress across PureTech’s portfolio, with significant near-term catalysts</i> </p><p class="bwalignc"> <i>Robust shareholder returns enabled by Founded Entity1 monetization; $100 million Tender Offer and </i><i>$50 million buyback completed</i> </p><p class="bwalignc"> <i>Strong balance sheet with expected operational runway for at least three years</i> </p><p class="bwalignc"> <i>Company to host a webcast and conference call today at 9:00am EDT / 2:00pm BST</i> </p> <p> BOSTON--(BUSINESS WIRE)-- PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announces its half-yearly results for the six months ended June 30, 2024. The following information will http://www.streetinsider.com/Press+Releases/PureTech+Health+plc%C2%A0%E2%80%93+Half-Year+Report/23653183.html Wed, 28 Aug 2024 02:01:00 -0400 A.01362791 A.06822034 A.09542560 A.21794726 A.26940647 A.27675538 A.31066700 A.31197700 A.37672378 A.40871480 A.50114120 A.60004854 A.60012007 A.60012014 AKLI BMY O.00000283 O.00384710 O.00417799 O.00638181 O.00831659 O.00831932 O.10864893 O.20026344 O.22422661 O.22973220 O.28834655 O.41197774 O.41343427 O.48279457 PRTC PRTC VOR http://www.streetinsider.com/Press+Releases/PureTech+Health+plc%C2%A0%E2%80%93+Half-Year+Report/23653183.html <p class="bwalignc"> <i>Strong progress across PureTech’s portfolio, with significant near-term catalysts</i> </p><p class="bwalignc"> <i>Robust shareholder returns enabled by Founded Entity1 monetization; $100 million Tender Offer and </i><i>$50 million buyback completed</i> </p><p class="bwalignc"> <i>Strong balance sheet with expected operational runway for at least three years</i> </p><p class="bwalignc"> <i>Company to host a webcast and conference call today at 9:00am EDT / 2:00pm BST</i> </p> <p> BOSTON--(BUSINESS WIRE)-- PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announces its half-yearly results for the six months ended June 30, 2024. The following information will http://www.streetinsider.com/Press+Releases/PureTech+Health+plc%C2%A0%E2%80%93+Half-Year+Report/23653183.html Wed, 28 Aug 2024 02:01:00 -0400 A.01362791 A.06822034 A.09542560 A.21794726 A.26940647 A.27675538 A.31066700 A.31197700 A.37672378 A.40871480 A.50114120 A.60004854 A.60012007 A.60012014 AKLI BMY O.00000283 O.00384710 O.00417799 O.00638181 O.00831659 O.00831932 O.10864893 O.20026344 O.22422661 O.22973220 O.28834655 O.41197774 O.41343427 O.48279457 PRTC PRTC VOR http://www.streetinsider.com/Press+Releases/PureTech+Health+plc%C2%A0%E2%80%93+Half-Year+Report/23653183.html <p class="bwalignc"> <i>Strong progress across PureTech’s portfolio, with significant near-term catalysts</i> </p><p class="bwalignc"> <i>Robust shareholder returns enabled by Founded Entity1 monetization; $100 million Tender Offer and </i><i>$50 million buyback completed</i> </p><p class="bwalignc"> <i>Strong balance sheet with expected operational runway for at least three years</i> </p><p class="bwalignc"> <i>Company to host a webcast and conference call today at 9:00am EDT / 2:00pm BST</i> </p> <p> BOSTON--(BUSINESS WIRE)-- PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announces its half-yearly results for the six months ended June 30, 2024. The following information will http://www.streetinsider.com/Press+Releases/PureTech+Health+plc%C2%A0%E2%80%93+Half-Year+Report/23653183.html Wed, 28 Aug 2024 02:01:00 -0400 A.01362791 A.06822034 A.09542560 A.21794726 A.26940647 A.27675538 A.31066700 A.31197700 A.37672378 A.40871480 A.50114120 A.60004854 A.60012007 A.60012014 AKLI BMY O.00000283 O.00384710 O.00417799 O.00638181 O.00831659 O.00831932 O.10864893 O.20026344 O.22422661 O.22973220 O.28834655 O.41197774 O.41343427 O.48279457 PRTC PRTC VOR http://www.streetinsider.com/Press+Releases/PureTech+Health+plc%C2%A0%E2%80%93+Half-Year+Report/23653183.html <p class="bwalignc"> <i>Strong progress across PureTech’s portfolio, with significant near-term catalysts</i> </p><p class="bwalignc"> <i>Robust shareholder returns enabled by Founded Entity1 monetization; $100 million Tender Offer and </i><i>$50 million buyback completed</i> </p><p class="bwalignc"> <i>Strong balance sheet with expected operational runway for at least three years</i> </p><p class="bwalignc"> <i>Company to host a webcast and conference call today at 9:00am EDT / 2:00pm BST</i> </p> <p> BOSTON--(BUSINESS WIRE)-- PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announces its half-yearly results for the six months ended June 30, 2024. The following information will http://www.streetinsider.com/Press+Releases/PureTech+Health+plc%C2%A0%E2%80%93+Half-Year+Report/23653183.html Wed, 28 Aug 2024 02:01:00 -0400 A.01362791 A.06822034 A.09542560 A.21794726 A.26940647 A.27675538 A.31066700 A.31197700 A.37672378 A.40871480 A.50114120 A.60004854 A.60012007 A.60012014 AKLI BMY O.00000283 O.00384710 O.00417799 O.00638181 O.00831659 O.00831932 O.10864893 O.20026344 O.22422661 O.22973220 O.28834655 O.41197774 O.41343427 O.48279457 PRTC PRTC VOR http://www.streetinsider.com/Press+Releases/PureTech+Health+plc%C2%A0%E2%80%93+Half-Year+Report/23653183.html <p class="bwalignc"> <i>Strong progress across PureTech’s portfolio, with significant near-term catalysts</i> </p><p class="bwalignc"> <i>Robust shareholder returns enabled by Founded Entity1 monetization; $100 million Tender Offer and </i><i>$50 million buyback completed</i> </p><p class="bwalignc"> <i>Strong balance sheet with expected operational runway for at least three years</i> </p><p class="bwalignc"> <i>Company to host a webcast and conference call today at 9:00am EDT / 2:00pm BST</i> </p> <p> BOSTON--(BUSINESS WIRE)-- PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announces its half-yearly results for the six months ended June 30, 2024. The following information will http://www.streetinsider.com/Press+Releases/PureTech+Health+plc%C2%A0%E2%80%93+Half-Year+Report/23653183.html Wed, 28 Aug 2024 02:01:00 -0400 A.01362791 A.06822034 A.09542560 A.21794726 A.26940647 A.27675538 A.31066700 A.31197700 A.37672378 A.40871480 A.50114120 A.60004854 A.60012007 A.60012014 AKLI BMY O.00000283 O.00384710 O.00417799 O.00638181 O.00831659 O.00831932 O.10864893 O.20026344 O.22422661 O.22973220 O.28834655 O.41197774 O.41343427 O.48279457 PRTC PRTC VOR http://www.streetinsider.com/Press+Releases/PureTech+Health+plc%C2%A0%E2%80%93+Half-Year+Report/23653183.html <p class="bwalignc"> <i>Strong progress across PureTech’s portfolio, with significant near-term catalysts</i> </p><p class="bwalignc"> <i>Robust shareholder returns enabled by Founded Entity1 monetization; $100 million Tender Offer and </i><i>$50 million buyback completed</i> </p><p class="bwalignc"> <i>Strong balance sheet with expected operational runway for at least three years</i> </p><p class="bwalignc"> <i>Company to host a webcast and conference call today at 9:00am EDT / 2:00pm BST</i> </p> <p> BOSTON--(BUSINESS WIRE)-- PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announces its half-yearly results for the six months ended June 30, 2024. The following information will http://www.streetinsider.com/Press+Releases/PureTech+Health+plc%C2%A0%E2%80%93+Half-Year+Report/23653183.html Wed, 28 Aug 2024 02:01:00 -0400 A.01362791 A.06822034 A.09542560 A.21794726 A.26940647 A.27675538 A.31066700 A.31197700 A.37672378 A.40871480 A.50114120 A.60004854 A.60012007 A.60012014 AKLI BMY O.00000283 O.00384710 O.00417799 O.00638181 O.00831659 O.00831932 O.10864893 O.20026344 O.22422661 O.22973220 O.28834655 O.41197774 O.41343427 O.48279457 PRTC PRTC VOR http://www.streetinsider.com/Press+Releases/PureTech+Health+plc%C2%A0%E2%80%93+Half-Year+Report/23653183.html <p class="bwalignc"> <i>Strong progress across PureTech’s portfolio, with significant near-term catalysts</i> </p><p class="bwalignc"> <i>Robust shareholder returns enabled by Founded Entity1 monetization; $100 million Tender Offer and </i><i>$50 million buyback completed</i> </p><p class="bwalignc"> <i>Strong balance sheet with expected operational runway for at least three years</i> </p><p class="bwalignc"> <i>Company to host a webcast and conference call today at 9:00am EDT / 2:00pm BST</i> </p> <p> BOSTON--(BUSINESS WIRE)-- PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announces its half-yearly results for the six months ended June 30, 2024. The following information will http://www.streetinsider.com/Press+Releases/PureTech+Health+plc%C2%A0%E2%80%93+Half-Year+Report/23653183.html Wed, 28 Aug 2024 02:01:00 -0400 A.01362791 A.06822034 A.09542560 A.21794726 A.26940647 A.27675538 A.31066700 A.31197700 A.37672378 A.40871480 A.50114120 A.60004854 A.60012007 A.60012014 AKLI BMY O.00000283 O.00384710 O.00417799 O.00638181 O.00831659 O.00831932 O.10864893 O.20026344 O.22422661 O.22973220 O.28834655 O.41197774 O.41343427 O.48279457 PRTC PRTC VOR http://www.streetinsider.com/Press+Releases/PureTech+Health+plc%C2%A0%E2%80%93+Half-Year+Report/23653183.html <p class="bwalignc"> <i>Strong progress across PureTech’s portfolio, with significant near-term catalysts</i> </p><p class="bwalignc"> <i>Robust shareholder returns enabled by Founded Entity1 monetization; $100 million Tender Offer and </i><i>$50 million buyback completed</i> </p><p class="bwalignc"> <i>Strong balance sheet with expected operational runway for at least three years</i> </p><p class="bwalignc"> <i>Company to host a webcast and conference call today at 9:00am EDT / 2:00pm BST</i> </p> <p> BOSTON--(BUSINESS WIRE)-- PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announces its half-yearly results for the six months ended June 30, 2024. The following information will http://www.streetinsider.com/Press+Releases/PureTech+Health+plc%C2%A0%E2%80%93+Half-Year+Report/23653183.html Wed, 28 Aug 2024 02:01:00 -0400 A.01362791 A.06822034 A.09542560 A.21794726 A.26940647 A.27675538 A.31066700 A.31197700 A.37672378 A.40871480 A.50114120 A.60004854 A.60012007 A.60012014 AKLI BMY O.00000283 O.00384710 O.00417799 O.00638181 O.00831659 O.00831932 O.10864893 O.20026344 O.22422661 O.22973220 O.28834655 O.41197774 O.41343427 O.48279457 PRTC PRTC VOR http://www.streetinsider.com/Press+Releases/PureTech+Health+plc%C2%A0%E2%80%93+Half-Year+Report/23653183.html <p class="bwalignc"> <i>Strong progress across PureTech’s portfolio, with significant near-term catalysts</i> </p><p class="bwalignc"> <i>Robust shareholder returns enabled by Founded Entity1 monetization; $100 million Tender Offer and </i><i>$50 million buyback completed</i> </p><p class="bwalignc"> <i>Strong balance sheet with expected operational runway for at least three years</i> </p><p class="bwalignc"> <i>Company to host a webcast and conference call today at 9:00am EDT / 2:00pm BST</i> </p> <p> BOSTON--(BUSINESS WIRE)-- PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announces its half-yearly results for the six months ended June 30, 2024. The following information will http://www.streetinsider.com/Press+Releases/PureTech+Health+plc%C2%A0%E2%80%93+Half-Year+Report/23653183.html Wed, 28 Aug 2024 02:01:00 -0400 A.01362791 A.06822034 A.09542560 A.21794726 A.26940647 A.27675538 A.31066700 A.31197700 A.37672378 A.40871480 A.50114120 A.60004854 A.60012007 A.60012014 AKLI BMY O.00000283 O.00384710 O.00417799 O.00638181 O.00831659 O.00831932 O.10864893 O.20026344 O.22422661 O.22973220 O.28834655 O.41197774 O.41343427 O.48279457 PRTC PRTC VOR http://www.streetinsider.com/Press+Releases/PureTech+Health+plc%C2%A0%E2%80%93+Half-Year+Report/23653183.html <p class="bwalignc"> <i>Strong progress across PureTech’s portfolio, with significant near-term catalysts</i> </p><p class="bwalignc"> <i>Robust shareholder returns enabled by Founded Entity1 monetization; $100 million Tender Offer and </i><i>$50 million buyback completed</i> </p><p class="bwalignc"> <i>Strong balance sheet with expected operational runway for at least three years</i> </p><p class="bwalignc"> <i>Company to host a webcast and conference call today at 9:00am EDT / 2:00pm BST</i> </p> <p> BOSTON--(BUSINESS WIRE)-- PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announces its half-yearly results for the six months ended June 30, 2024. The following information will http://www.streetinsider.com/Press+Releases/PureTech+Health+plc%C2%A0%E2%80%93+Half-Year+Report/23653183.html Wed, 28 Aug 2024 02:01:00 -0400 A.01362791 A.06822034 A.09542560 A.21794726 A.26940647 A.27675538 A.31066700 A.31197700 A.37672378 A.40871480 A.50114120 A.60004854 A.60012007 A.60012014 AKLI BMY O.00000283 O.00384710 O.00417799 O.00638181 O.00831659 O.00831932 O.10864893 O.20026344 O.22422661 O.22973220 O.28834655 O.41197774 O.41343427 O.48279457 PRTC PRTC VOR http://www.streetinsider.com/Press+Releases/PureTech+Health+plc%C2%A0%E2%80%93+Half-Year+Report/23653183.html <p class="bwalignc"> <i>Strong progress across PureTech’s portfolio, with significant near-term catalysts</i> </p><p class="bwalignc"> <i>Robust shareholder returns enabled by Founded Entity1 monetization; $100 million Tender Offer and </i><i>$50 million buyback completed</i> </p><p class="bwalignc"> <i>Strong balance sheet with expected operational runway for at least three years</i> </p><p class="bwalignc"> <i>Company to host a webcast and conference call today at 9:00am EDT / 2:00pm BST</i> </p> <p> BOSTON--(BUSINESS WIRE)-- PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announces its half-yearly results for the six months ended June 30, 2024. The following information will http://www.streetinsider.com/Press+Releases/PureTech+Health+plc%C2%A0%E2%80%93+Half-Year+Report/23653183.html Wed, 28 Aug 2024 02:01:00 -0400 A.01362791 A.06822034 A.09542560 A.21794726 A.26940647 A.27675538 A.31066700 A.31197700 A.37672378 A.40871480 A.50114120 A.60004854 A.60012007 A.60012014 AKLI BMY O.00000283 O.00384710 O.00417799 O.00638181 O.00831659 O.00831932 O.10864893 O.20026344 O.22422661 O.22973220 O.28834655 O.41197774 O.41343427 O.48279457 PRTC PRTC VOR http://www.streetinsider.com/Press+Releases/PureTech+Health+plc%C2%A0%E2%80%93+Half-Year+Report/23653183.html <p class="bwalignc"> <i>Strong progress across PureTech’s portfolio, with significant near-term catalysts</i> </p><p class="bwalignc"> <i>Robust shareholder returns enabled by Founded Entity1 monetization; $100 million Tender Offer and </i><i>$50 million buyback completed</i> </p><p class="bwalignc"> <i>Strong balance sheet with expected operational runway for at least three years</i> </p><p class="bwalignc"> <i>Company to host a webcast and conference call today at 9:00am EDT / 2:00pm BST</i> </p> <p> BOSTON--(BUSINESS WIRE)-- PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announces its half-yearly results for the six months ended June 30, 2024. The following information will http://www.streetinsider.com/Press+Releases/PureTech+Health+plc%C2%A0%E2%80%93+Half-Year+Report/23653183.html Wed, 28 Aug 2024 02:01:00 -0400 A.01362791 A.06822034 A.09542560 A.21794726 A.26940647 A.27675538 A.31066700 A.31197700 A.37672378 A.40871480 A.50114120 A.60004854 A.60012007 A.60012014 AKLI BMY O.00000283 O.00384710 O.00417799 O.00638181 O.00831659 O.00831932 O.10864893 O.20026344 O.22422661 O.22973220 O.28834655 O.41197774 O.41343427 O.48279457 PRTC PRTC VOR http://www.streetinsider.com/Press+Releases/PureTech+Health+plc%C2%A0%E2%80%93+Half-Year+Report/23653183.html <p class="bwalignc"> <i>Strong progress across PureTech’s portfolio, with significant near-term catalysts</i> </p><p class="bwalignc"> <i>Robust shareholder returns enabled by Founded Entity1 monetization; $100 million Tender Offer and </i><i>$50 million buyback completed</i> </p><p class="bwalignc"> <i>Strong balance sheet with expected operational runway for at least three years</i> </p><p class="bwalignc"> <i>Company to host a webcast and conference call today at 9:00am EDT / 2:00pm BST</i> </p> <p> BOSTON--(BUSINESS WIRE)-- PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announces its half-yearly results for the six months ended June 30, 2024. The following information will http://www.streetinsider.com/Press+Releases/PureTech+Health+plc%C2%A0%E2%80%93+Half-Year+Report/23653183.html Wed, 28 Aug 2024 02:01:00 -0400 A.01362791 A.06822034 A.09542560 A.21794726 A.26940647 A.27675538 A.31066700 A.31197700 A.37672378 A.40871480 A.50114120 A.60004854 A.60012007 A.60012014 AKLI BMY O.00000283 O.00384710 O.00417799 O.00638181 O.00831659 O.00831932 O.10864893 O.20026344 O.22422661 O.22973220 O.28834655 O.41197774 O.41343427 O.48279457 PRTC PRTC VOR http://www.streetinsider.com/Press+Releases/PureTech+Health+plc%C2%A0%E2%80%93+Half-Year+Report/23653183.html <p class="bwalignc"> <i>Strong progress across PureTech’s portfolio, with significant near-term catalysts</i> </p><p class="bwalignc"> <i>Robust shareholder returns enabled by Founded Entity1 monetization; $100 million Tender Offer and </i><i>$50 million buyback completed</i> </p><p class="bwalignc"> <i>Strong balance sheet with expected operational runway for at least three years</i> </p><p class="bwalignc"> <i>Company to host a webcast and conference call today at 9:00am EDT / 2:00pm BST</i> </p> <p> BOSTON--(BUSINESS WIRE)-- PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announces its half-yearly results for the six months ended June 30, 2024. The following information will http://www.streetinsider.com/Press+Releases/PureTech+Health+plc%C2%A0%E2%80%93+Half-Year+Report/23653183.html Wed, 28 Aug 2024 02:01:00 -0400 A.01362791 A.06822034 A.09542560 A.21794726 A.26940647 A.27675538 A.31066700 A.31197700 A.37672378 A.40871480 A.50114120 A.60004854 A.60012007 A.60012014 AKLI BMY O.00000283 O.00384710 O.00417799 O.00638181 O.00831659 O.00831932 O.10864893 O.20026344 O.22422661 O.22973220 O.28834655 O.41197774 O.41343427 O.48279457 PRTC PRTC VOR http://www.streetinsider.com/Press+Releases/PureTech+Health+plc%C2%A0%E2%80%93+Half-Year+Report/23653183.html <p class="bwalignc"> <i>Strong progress across PureTech’s portfolio, with significant near-term catalysts</i> </p><p class="bwalignc"> <i>Robust shareholder returns enabled by Founded Entity1 monetization; $100 million Tender Offer and </i><i>$50 million buyback completed</i> </p><p class="bwalignc"> <i>Strong balance sheet with expected operational runway for at least three years</i> </p><p class="bwalignc"> <i>Company to host a webcast and conference call today at 9:00am EDT / 2:00pm BST</i> </p> <p> BOSTON--(BUSINESS WIRE)-- PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announces its half-yearly results for the six months ended June 30, 2024. The following information will http://www.streetinsider.com/Press+Releases/PureTech+Health+plc%C2%A0%E2%80%93+Half-Year+Report/23653183.html Wed, 28 Aug 2024 02:01:00 -0400 A.01362791 A.06822034 A.09542560 A.21794726 A.26940647 A.27675538 A.31066700 A.31197700 A.37672378 A.40871480 A.50114120 A.60004854 A.60012007 A.60012014 AKLI BMY O.00000283 O.00384710 O.00417799 O.00638181 O.00831659 O.00831932 O.10864893 O.20026344 O.22422661 O.22973220 O.28834655 O.41197774 O.41343427 O.48279457 PRTC PRTC VOR http://www.streetinsider.com/Press+Releases/PureTech+Health+plc%C2%A0%E2%80%93+Half-Year+Report/23653183.html <p class="bwalignc"> <i>Strong progress across PureTech’s portfolio, with significant near-term catalysts</i> </p><p class="bwalignc"> <i>Robust shareholder returns enabled by Founded Entity1 monetization; $100 million Tender Offer and </i><i>$50 million buyback completed</i> </p><p class="bwalignc"> <i>Strong balance sheet with expected operational runway for at least three years</i> </p><p class="bwalignc"> <i>Company to host a webcast and conference call today at 9:00am EDT / 2:00pm BST</i> </p> <p> BOSTON--(BUSINESS WIRE)-- PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announces its half-yearly results for the six months ended June 30, 2024. The following information will http://www.streetinsider.com/Press+Releases/PureTech+Health+plc%C2%A0%E2%80%93+Half-Year+Report/23653183.html Wed, 28 Aug 2024 02:01:00 -0400 A.01362791 A.06822034 A.09542560 A.21794726 A.26940647 A.27675538 A.31066700 A.31197700 A.37672378 A.40871480 A.50114120 A.60004854 A.60012007 A.60012014 AKLI BMY O.00000283 O.00384710 O.00417799 O.00638181 O.00831659 O.00831932 O.10864893 O.20026344 O.22422661 O.22973220 O.28834655 O.41197774 O.41343427 O.48279457 PRTC PRTC VOR http://www.streetinsider.com/Press+Releases/PureTech+Health+plc%C2%A0%E2%80%93+Half-Year+Report/23653183.html <p class="bwalignc"> <i>Strong progress across PureTech’s portfolio, with significant near-term catalysts</i> </p><p class="bwalignc"> <i>Robust shareholder returns enabled by Founded Entity1 monetization; $100 million Tender Offer and </i><i>$50 million buyback completed</i> </p><p class="bwalignc"> <i>Strong balance sheet with expected operational runway for at least three years</i> </p><p class="bwalignc"> <i>Company to host a webcast and conference call today at 9:00am EDT / 2:00pm BST</i> </p> <p> BOSTON--(BUSINESS WIRE)-- PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announces its half-yearly results for the six months ended June 30, 2024. The following information will http://www.streetinsider.com/Press+Releases/PureTech+Health+plc%C2%A0%E2%80%93+Half-Year+Report/23653183.html Wed, 28 Aug 2024 02:01:00 -0400 A.01362791 A.06822034 A.09542560 A.21794726 A.26940647 A.27675538 A.31066700 A.31197700 A.37672378 A.40871480 A.50114120 A.60004854 A.60012007 A.60012014 AKLI BMY O.00000283 O.00384710 O.00417799 O.00638181 O.00831659 O.00831932 O.10864893 O.20026344 O.22422661 O.22973220 O.28834655 O.41197774 O.41343427 O.48279457 PRTC PRTC VOR http://www.streetinsider.com/Press+Releases/PureTech+Health+plc%C2%A0%E2%80%93+Half-Year+Report/23653183.html <p class="bwalignc"> <i>Strong progress across PureTech’s portfolio, with significant near-term catalysts</i> </p><p class="bwalignc"> <i>Robust shareholder returns enabled by Founded Entity1 monetization; $100 million Tender Offer and </i><i>$50 million buyback completed</i> </p><p class="bwalignc"> <i>Strong balance sheet with expected operational runway for at least three years</i> </p><p class="bwalignc"> <i>Company to host a webcast and conference call today at 9:00am EDT / 2:00pm BST</i> </p> <p> BOSTON--(BUSINESS WIRE)-- PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announces its half-yearly results for the six months ended June 30, 2024. The following information will http://www.streetinsider.com/Press+Releases/PureTech+Health+plc%C2%A0%E2%80%93+Half-Year+Report/23653183.html Wed, 28 Aug 2024 02:01:00 -0400 A.01362791 A.06822034 A.09542560 A.21794726 A.26940647 A.27675538 A.31066700 A.31197700 A.37672378 A.40871480 A.50114120 A.60004854 A.60012007 A.60012014 AKLI BMY O.00000283 O.00384710 O.00417799 O.00638181 O.00831659 O.00831932 O.10864893 O.20026344 O.22422661 O.22973220 O.28834655 O.41197774 O.41343427 O.48279457 PRTC PRTC VOR http://www.streetinsider.com/Press+Releases/PureTech+Health+plc%C2%A0%E2%80%93+Half-Year+Report/23653183.html <p class="bwalignc"> <i>Strong progress across PureTech’s portfolio, with significant near-term catalysts</i> </p><p class="bwalignc"> <i>Robust shareholder returns enabled by Founded Entity1 monetization; $100 million Tender Offer and </i><i>$50 million buyback completed</i> </p><p class="bwalignc"> <i>Strong balance sheet with expected operational runway for at least three years</i> </p><p class="bwalignc"> <i>Company to host a webcast and conference call today at 9:00am EDT / 2:00pm BST</i> </p> <p> BOSTON--(BUSINESS WIRE)-- PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announces its half-yearly results for the six months ended June 30, 2024. The following information will http://www.streetinsider.com/Press+Releases/PureTech+Health+plc%C2%A0%E2%80%93+Half-Year+Report/23653183.html Wed, 28 Aug 2024 02:01:00 -0400 A.01362791 A.06822034 A.09542560 A.21794726 A.26940647 A.27675538 A.31066700 A.31197700 A.37672378 A.40871480 A.50114120 A.60004854 A.60012007 A.60012014 AKLI BMY O.00000283 O.00384710 O.00417799 O.00638181 O.00831659 O.00831932 O.10864893 O.20026344 O.22422661 O.22973220 O.28834655 O.41197774 O.41343427 O.48279457 PRTC PRTC VOR http://www.streetinsider.com/Press+Releases/PureTech+Health+plc%C2%A0%E2%80%93+Half-Year+Report/23653183.html <p class="bwalignc"> <i>Strong progress across PureTech’s portfolio, with significant near-term catalysts</i> </p><p class="bwalignc"> <i>Robust shareholder returns enabled by Founded Entity1 monetization; $100 million Tender Offer and </i><i>$50 million buyback completed</i> </p><p class="bwalignc"> <i>Strong balance sheet with expected operational runway for at least three years</i> </p><p class="bwalignc"> <i>Company to host a webcast and conference call today at 9:00am EDT / 2:00pm BST</i> </p> <p> BOSTON--(BUSINESS WIRE)-- PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announces its half-yearly results for the six months ended June 30, 2024. The following information will http://www.streetinsider.com/Press+Releases/PureTech+Health+plc%C2%A0%E2%80%93+Half-Year+Report/23653183.html Wed, 28 Aug 2024 02:01:00 -0400 A.01362791 A.06822034 A.09542560 A.21794726 A.26940647 A.27675538 A.31066700 A.31197700 A.37672378 A.40871480 A.50114120 A.60004854 A.60012007 A.60012014 AKLI BMY O.00000283 O.00384710 O.00417799 O.00638181 O.00831659 O.00831932 O.10864893 O.20026344 O.22422661 O.22973220 O.28834655 O.41197774 O.41343427 O.48279457 PRTC PRTC VOR http://www.streetinsider.com/Press+Releases/PureTech+Health+plc%C2%A0%E2%80%93+Half-Year+Report/23653183.html <p class="bwalignc"> <i>Strong progress across PureTech’s portfolio, with significant near-term catalysts</i> </p><p class="bwalignc"> <i>Robust shareholder returns enabled by Founded Entity1 monetization; $100 million Tender Offer and </i><i>$50 million buyback completed</i> </p><p class="bwalignc"> <i>Strong balance sheet with expected operational runway for at least three years</i> </p><p class="bwalignc"> <i>Company to host a webcast and conference call today at 9:00am EDT / 2:00pm BST</i> </p> <p> BOSTON--(BUSINESS WIRE)-- PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announces its half-yearly results for the six months ended June 30, 2024. The following information will http://www.streetinsider.com/Press+Releases/PureTech+Health+plc%C2%A0%E2%80%93+Half-Year+Report/23653183.html Wed, 28 Aug 2024 02:01:00 -0400 A.01362791 A.06822034 A.09542560 A.21794726 A.26940647 A.27675538 A.31066700 A.31197700 A.37672378 A.40871480 A.50114120 A.60004854 A.60012007 A.60012014 AKLI BMY O.00000283 O.00384710 O.00417799 O.00638181 O.00831659 O.00831932 O.10864893 O.20026344 O.22422661 O.22973220 O.28834655 O.41197774 O.41343427 O.48279457 PRTC PRTC VOR http://www.streetinsider.com/Press+Releases/PureTech+Health+plc%C2%A0%E2%80%93+Half-Year+Report/23653183.html <p class="bwalignc"> <i>Strong progress across PureTech’s portfolio, with significant near-term catalysts</i> </p><p class="bwalignc"> <i>Robust shareholder returns enabled by Founded Entity1 monetization; $100 million Tender Offer and </i><i>$50 million buyback completed</i> </p><p class="bwalignc"> <i>Strong balance sheet with expected operational runway for at least three years</i> </p><p class="bwalignc"> <i>Company to host a webcast and conference call today at 9:00am EDT / 2:00pm BST</i> </p> <p> BOSTON--(BUSINESS WIRE)-- PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announces its half-yearly results for the six months ended June 30, 2024. The following information will http://www.streetinsider.com/Press+Releases/PureTech+Health+plc%C2%A0%E2%80%93+Half-Year+Report/23653183.html Wed, 28 Aug 2024 02:01:00 -0400 A.01362791 A.06822034 A.09542560 A.21794726 A.26940647 A.27675538 A.31066700 A.31197700 A.37672378 A.40871480 A.50114120 A.60004854 A.60012007 A.60012014 AKLI BMY O.00000283 O.00384710 O.00417799 O.00638181 O.00831659 O.00831932 O.10864893 O.20026344 O.22422661 O.22973220 O.28834655 O.41197774 O.41343427 O.48279457 PRTC PRTC VOR http://www.streetinsider.com/Press+Releases/PureTech+Health+plc%C2%A0%E2%80%93+Half-Year+Report/23653183.html <p class="bwalignc"> <i>Strong progress across PureTech’s portfolio, with significant near-term catalysts</i> </p><p class="bwalignc"> <i>Robust shareholder returns enabled by Founded Entity1 monetization; $100 million Tender Offer and </i><i>$50 million buyback completed</i> </p><p class="bwalignc"> <i>Strong balance sheet with expected operational runway for at least three years</i> </p><p class="bwalignc"> <i>Company to host a webcast and conference call today at 9:00am EDT / 2:00pm BST</i> </p> <p> BOSTON--(BUSINESS WIRE)-- PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announces its half-yearly results for the six months ended June 30, 2024. The following information will http://www.streetinsider.com/Press+Releases/PureTech+Health+plc%C2%A0%E2%80%93+Half-Year+Report/23653183.html Wed, 28 Aug 2024 02:01:00 -0400 A.01362791 A.06822034 A.09542560 A.21794726 A.26940647 A.27675538 A.31066700 A.31197700 A.37672378 A.40871480 A.50114120 A.60004854 A.60012007 A.60012014 AKLI BMY O.00000283 O.00384710 O.00417799 O.00638181 O.00831659 O.00831932 O.10864893 O.20026344 O.22422661 O.22973220 O.28834655 O.41197774 O.41343427 O.48279457 PRTC PRTC VOR http://www.streetinsider.com/Press+Releases/PureTech+Health+plc%C2%A0%E2%80%93+Half-Year+Report/23653183.html <p class="bwalignc"> <i>Strong progress across PureTech’s portfolio, with significant near-term catalysts</i> </p><p class="bwalignc"> <i>Robust shareholder returns enabled by Founded Entity1 monetization; $100 million Tender Offer and </i><i>$50 million buyback completed</i> </p><p class="bwalignc"> <i>Strong balance sheet with expected operational runway for at least three years</i> </p><p class="bwalignc"> <i>Company to host a webcast and conference call today at 9:00am EDT / 2:00pm BST</i> </p> <p> BOSTON--(BUSINESS WIRE)-- PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announces its half-yearly results for the six months ended June 30, 2024. The following information will http://www.streetinsider.com/Press+Releases/PureTech+Health+plc%C2%A0%E2%80%93+Half-Year+Report/23653183.html Wed, 28 Aug 2024 02:01:00 -0400 A.01362791 A.06822034 A.09542560 A.21794726 A.26940647 A.27675538 A.31066700 A.31197700 A.37672378 A.40871480 A.50114120 A.60004854 A.60012007 A.60012014 AKLI BMY O.00000283 O.00384710 O.00417799 O.00638181 O.00831659 O.00831932 O.10864893 O.20026344 O.22422661 O.22973220 O.28834655 O.41197774 O.41343427 O.48279457 PRTC PRTC VOR